Benzinga · Nov 3, 2026
Apple To $350? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for TEM, TWLO, UPWK, MRSH and PLTR; cut MRVL and AAPL targets, with upgrades for TWLO and MRSH.
SN
NASDAQ · SNDX
Syndax Pharmaceuticals, Inc.
Healthcare · Biotechnology
$14.29
Down-$3.58 (-25.05%)
Updated Nov 4, 2026, 4:31 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.77B
- P/E ratio
- -5.67
- Dividend yield
- 0.00%
- 52-week range
- $12.80 – $25.59
- Volume
- 4.98M
- Avg. volume
- 2.74M
Price performance · SNDX
SNDX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
SNDX closed at $14.29 after 21 trading sessions, down 17.73% for the selected period.
- Last close
- $14.29
- Period change
- -17.73%
- Period low
- $12.90
- Period high
- $17.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $13.08 | $14.485 | $13.06 | $14.29 | 4.98M |
| Nov 2, 2026 | $13.62 | $13.77 | $12.90 | $13.10 | 3.18M |
| Oct 30, 2026 | $14.06 | $14.35 | $13.61 | $13.65 | 2.54M |
| Oct 29, 2026 | $14.36 | $14.655 | $13.98 | $14.15 | 4.88M |
| Oct 28, 2026 | $13.52 | $14.34 | $13.49 | $14.32 | 2.75M |
| Oct 27, 2026 | $13.25 | $13.88 | $13.05 | $13.69 | 2.7M |
| Oct 26, 2026 | $13.58 | $13.70 | $13.12 | $13.22 | 1.99M |
| Oct 23, 2026 | $13.60 | $13.608 | $13.20 | $13.40 | 4.25M |
| Oct 22, 2026 | $13.06 | $13.58 | $13.05 | $13.57 | 2.36M |
| Oct 21, 2026 | $13.32 | $13.5871 | $13.10 | $13.15 | 2.59M |
| Oct 20, 2026 | $13.20 | $13.59 | $12.97 | $13.25 | 3.91M |
| Oct 19, 2026 | $12.95 | $13.18 | $12.795 | $13.09 | 2.19M |
| Oct 16, 2026 | $13.65 | $13.655 | $12.815 | $12.90 | 2.84M |
| Oct 15, 2026 | $13.58 | $14.05 | $13.43 | $13.65 | 2.63M |
| Oct 14, 2026 | $13.92 | $14.005 | $13.39 | $13.53 | 3.04M |
| Oct 13, 2026 | $14.61 | $14.74 | $13.49 | $13.95 | 6.81M |
| Oct 12, 2026 | $16.88 | $16.95 | $16.37 | $16.55 | 2.03M |
| Oct 9, 2026 | $16.91 | $17.42 | $16.78 | $16.99 | 1.46M |
| Oct 8, 2026 | $16.90 | $17.285 | $16.39 | $16.90 | 2.14M |
| Oct 7, 2026 | $17.17 | $17.695 | $17.03 | $17.03 | 1.59M |
| Oct 6, 2026 | $17.99 | $18.19 | $16.85 | $17.37 | 1.14M |
Latest SNDX news
The latest Smart Investors Daily articles mentioning SNDX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SNDX research
Overview
Company profile and research snapshot.
Company profile
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $33.75
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 13, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 21, 2026 | UBS | Buy | — |
| Aug 11, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Nov 3, 2026
HC Wainwright & Co. Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $36
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $36.
Yahoo · Nov 3, 2026
Syndax Pharmaceuticals (SNDX) Missed On Q3 Results, Is The 65% Undervaluation Case Still Intact?
Why Syndax Pharmaceuticals Stock Is Back in Focus After Q3 Results Syndax Pharmaceuticals (SNDX) moved into the spotlight after reporting third quarter 2026 results, with revenue of US$83.3 million and a net loss of US$49.43 million from continuing operations. The earnings miss and CFO transition have come against a weaker tape, with Syndax Pharmaceuticals’ share price down 25.57% over the past month and 31.34% over 90 days, while the 1 year total shareholder return has declined 4.80%. This...
Yahoo · Nov 3, 2026
Syndax (SNDX) Q3 2026 Earnings Call Transcript
Revenue surged 82% year-over-year as Revuforj and Niktimvo drive commercial momentum.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
